CY1111925T1 - Κιναση της θυμιδινης - Google Patents

Κιναση της θυμιδινης

Info

Publication number
CY1111925T1
CY1111925T1 CY20111100964T CY111100964T CY1111925T1 CY 1111925 T1 CY1111925 T1 CY 1111925T1 CY 20111100964 T CY20111100964 T CY 20111100964T CY 111100964 T CY111100964 T CY 111100964T CY 1111925 T1 CY1111925 T1 CY 1111925T1
Authority
CY
Cyprus
Prior art keywords
nucleotides
thymidine
movement
polynucleotide
replaced
Prior art date
Application number
CY20111100964T
Other languages
English (en)
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32750189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111925(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of CY1111925T1 publication Critical patent/CY1111925T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Ένα πολυνουκλεοτίδιο που περιλαμβάνει μια αλληλουχία νουκλεοτιδίων που κωδικοποιεί μια κινάση της θυμιδίνης όπου τουλάχιστον ένα από τα νουκλεοτίδια που αντιστοιχεί στα νουκλεοτίδια της θέσης ματίσματος του δότη αντικαθίσταται από ένα άλλο νουκλεοτίδιο και όπου τα νουκλεοτίδια των θέσεων ματίσματος του λήπτη δεν είναι αλλοιωμένα.
CY20111100964T 2004-06-18 2011-10-10 Κιναση της θυμιδινης CY1111925T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413702.2A GB0413702D0 (en) 2004-06-18 2004-06-18 Thymidine kinase
EP05766582A EP1781789B1 (en) 2004-06-18 2005-06-17 Thymidine kinase

Publications (1)

Publication Number Publication Date
CY1111925T1 true CY1111925T1 (el) 2015-11-04

Family

ID=32750189

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100964T CY1111925T1 (el) 2004-06-18 2011-10-10 Κιναση της θυμιδινης
CY2016054C CY2016054I1 (el) 2004-06-18 2016-12-28 Κιναση της θυμιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016054C CY2016054I1 (el) 2004-06-18 2016-12-28 Κιναση της θυμιδινης

Country Status (20)

Country Link
US (5) US8357788B2 (el)
EP (1) EP1781789B1 (el)
JP (1) JP5091669B2 (el)
KR (1) KR101337210B1 (el)
CN (1) CN101010428B (el)
AT (1) ATE520779T1 (el)
AU (1) AU2005254807B2 (el)
CA (1) CA2569304C (el)
CY (2) CY1111925T1 (el)
DK (1) DK1781789T3 (el)
ES (1) ES2372022T3 (el)
GB (1) GB0413702D0 (el)
HU (1) HUS1600064I1 (el)
IL (2) IL179660A (el)
LT (1) LTC1781789I2 (el)
NL (1) NL300856I2 (el)
PL (1) PL1781789T3 (el)
PT (1) PT1781789E (el)
SI (1) SI1781789T1 (el)
WO (1) WO2005123912A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
US20140248695A1 (en) 2011-10-05 2014-09-04 MolMed, S.p.A. Viral Vectors Purification System
AU2018395012B2 (en) 2017-12-28 2022-03-10 Bionoxx Inc. Oncolytic virus improved in safety and anticancer effect
US11157042B1 (en) 2018-03-28 2021-10-26 Douglas Patton Systems and methods for interaction of wearable communication devices
KR20210016567A (ko) 2018-05-30 2021-02-16 글리코스템 떼라퓨틱스 비.브이. Car nk 세포
CA3139643A1 (en) * 2019-06-27 2020-12-30 Bionoxx Inc. Oncolytic virus with improved safety and anticancer effects
WO2025168661A1 (en) 2024-02-05 2025-08-14 Ospedale San Raffaele S.R.L. Chimeric antigen receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DE69033975T2 (de) 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1261847B (it) 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0758387B1 (en) 1994-05-02 2001-12-19 University of Washington Thymidine kinase mutants
FR2751988B1 (fr) 1996-08-01 1998-09-11 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
BR9707483A (pt) * 1996-02-09 1999-04-06 Rhone Poulenc Rorer Sa Sequência de ácidos nucléicos que codificam para uma timidina quinase variante de uma timidina quinase selvagem variante de uma timidina quinase do vírus do herpes simplex de tipo 1 veículo de expressão vetor e composição farmacêutica
FR2744731B1 (fr) 1996-02-09 1998-05-22 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
WO1997037542A1 (en) 1996-04-10 1997-10-16 University Of Southern California Gene therapy for proliferative vitreoretinopathy
EP1886677A1 (en) 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
EP1025212B1 (en) 1997-10-14 2007-09-26 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
CN1273587C (zh) * 2002-06-05 2006-09-06 上海新世界基因技术开发有限公司 疱疹病毒胸苷激酶突变体及其应用
EP1428886B1 (de) 2002-12-09 2009-08-05 Celltech GmbH Biotechnologie Verbesserte retrovirale Vektoren für die Gentherapie
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase

Also Published As

Publication number Publication date
CA2569304C (en) 2014-08-12
US8357788B2 (en) 2013-01-22
US20090130069A1 (en) 2009-05-21
US20130028876A1 (en) 2013-01-31
PT1781789E (pt) 2011-10-20
CN101010428A (zh) 2007-08-01
JP2008502342A (ja) 2008-01-31
US20150231275A1 (en) 2015-08-20
IL179660A (en) 2012-12-31
JP5091669B2 (ja) 2012-12-05
US8642311B2 (en) 2014-02-04
ATE520779T1 (de) 2011-09-15
WO2005123912A2 (en) 2005-12-29
WO2005123912A3 (en) 2006-05-04
US20140178345A1 (en) 2014-06-26
KR20070032786A (ko) 2007-03-22
AU2005254807A1 (en) 2005-12-29
KR101337210B1 (ko) 2013-12-06
DK1781789T3 (da) 2011-11-28
CY2016054I2 (el) 2017-07-12
CA2569304A1 (en) 2005-12-29
HK1097881A1 (en) 2007-07-06
SI1781789T1 (sl) 2012-03-30
US9005945B2 (en) 2015-04-14
CN101010428B (zh) 2013-10-02
EP1781789B1 (en) 2011-08-17
IL213084A0 (en) 2011-07-31
LTC1781789I2 (lt) 2018-10-10
ES2372022T3 (es) 2012-01-13
AU2005254807B2 (en) 2011-08-18
EP1781789A2 (en) 2007-05-09
IL179660A0 (en) 2007-05-15
US10314925B2 (en) 2019-06-11
LTPA2016047I1 (lt) 2017-01-25
NL300856I2 (el) 2017-04-20
HUS1600064I1 (hu) 2017-02-28
CY2016054I1 (el) 2017-07-12
US10155052B2 (en) 2018-12-18
GB0413702D0 (en) 2004-07-21
US20190070312A1 (en) 2019-03-07
PL1781789T3 (pl) 2011-12-30

Similar Documents

Publication Publication Date Title
CY2018019I2 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
LTC1781789I2 (lt) Timidinkinazė
CY2016052I2 (el) Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων
LTC1849470I2 (lt) Priešvėžinis vaistas, turintis alfa, alfa, alfa-trifluortimidino ir timidinfosforilazės inhibitorių
CY1117139T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνης κινασης τυροσινης
DK3266791T3 (da) Mærkede nukleotider
EP1495141A4 (en) THERAPY OF HIV
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
EP1497655A4 (en) IMPROVED GENE EXPRESSION SYSTEM
ATE474614T1 (de) Verbesserter pen-injektor
DE602005021040D1 (de) Elektrochirurgisches System mit Vielzahl von Elektroden
ATE538127T1 (de) 6-disubstituierte bicyclische nukleinsäureanaloga
DK1957528T3 (da) Nukleotid-vaccine
CY1106422T1 (el) Επιπλεον νεες μορφες παρεμβαλλομενου rna
DE60335772D1 (de) Methode, elektronische Anordnungen mittels Mikrokanälen herzustellen
DE602005020229D1 (de) Schaufel mit prallgekühltem Übergang von grossem Krümmungsradius
BRPI0412856A2 (pt) trava extensível de múliplos pontos aperfeiçoada
CY1117599T1 (el) Σουλφοναμιδια για την προληψη του διαβητη
DK1765844T3 (da) Purin-nukleotidderivater
DE602004017676D1 (de) Mit Peroxiden haertbare Butylformulierungen
LU91028B1 (fr) Brique améliorée.
FR2853906B1 (fr) N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications
ITPD20030144A1 (it) Pannello di comando touch control di tipo capacitivo
ITGO20080006A1 (it) Serratura utilizzabile con chiavi di diverso tipo
FI20030211A0 (fi) Pohjalevytön kalliokärki